Literature DB >> 26567701

Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.

Chiara Degirolamo1,2,3, Carlo Sabbà1, Antonio Moschetta1,2.   

Abstract

The endocrine fibroblast growth factors (FGFs), FGF19, FGF21 and FGF23, are critical for maintaining whole-body homeostasis, with roles in bile acid, glucose and lipid metabolism, modulation of vitamin D and phosphate homeostasis and metabolic adaptation during fasting. Given these functions, the endocrine FGFs have therapeutic potential in a wide array of chronic human diseases, including obesity, type 2 diabetes, cancer, and kidney and cardiovascular disease. However, the safety and feasibility of chronic endocrine FGF administration has been challenged, and FGF analogues and mimetics are now being investigated. Here, we discuss current knowledge of the complex biology of the endocrine FGFs and assess how this may be harnessed therapeutically.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26567701     DOI： 10.1038/nrd.2015.9

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  237 in total

1.  Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.

Authors:  Masahiro Koizumi; Hirotaka Komaba; Shohei Nakanishi; Akira Fujimori; Masafumi Fukagawa
Journal:  Nephrol Dial Transplant       Date:  2011-07-05       Impact factor: 5.992

2.  Chemical generation of bispecific antibodies.

Authors:  Venkata R Doppalapudi; Jie Huang; Dingguo Liu; Ping Jin; Bin Liu; Lingna Li; Joel Desharnais; Crystal Hagen; Nancy J Levin; Michael J Shields; Michelle Parish; Robert E Murphy; Joselyn Del Rosario; Bryan D Oates; Jing-Yu Lai; Marla J Matin; Zemeda Ainekulu; Abhijit Bhat; Curt W Bradshaw; Gary Woodnutt; Richard A Lerner; Rodney W Lappe
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-13       Impact factor: 11.205

3.  Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19).

Authors:  Xinle Wu; Hongfei Ge; Bryan Lemon; Steven Vonderfecht; Helene Baribault; Jennifer Weiszmann; Jamila Gupte; Jonitha Gardner; Richard Lindberg; Zhulun Wang; Yang Li
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-26       Impact factor: 11.205

4.  Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats.

Authors:  David A Sarruf; Joshua P Thaler; Gregory J Morton; Jonathan German; Jonathan D Fischer; Kayoko Ogimoto; Michael W Schwartz
Journal:  Diabetes       Date:  2010-03-31       Impact factor: 9.461

5.  Bile acid signaling pathways increase stability of Small Heterodimer Partner (SHP) by inhibiting ubiquitin-proteasomal degradation.

Authors:  Ji Miao; Zhen Xiao; Deepthi Kanamaluru; Gyesik Min; Peter M Yau; Timothy D Veenstra; Ewa Ellis; Steve Strom; Kelly Suino-Powell; H Eric Xu; Jongsook Kim Kemper
Journal:  Genes Dev       Date:  2009-04-15       Impact factor: 11.361

6.  Liver-specific activities of FGF19 require Klotho beta.

Authors:  Benjamin C Lin; Manping Wang; Craig Blackmore; Luc R Desnoyers
Journal:  J Biol Chem       Date:  2007-07-11       Impact factor: 5.157

7.  Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by PXR.

Authors:  Wolfgang Wistuba; Carsten Gnewuch; Gerhard Liebisch; Gerd Schmitz; Thomas Langmann
Journal:  World J Gastroenterol       Date:  2007-08-21       Impact factor: 5.742

8.  Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease.

Authors:  Orlando M Gutiérrez; James L Januzzi; Tamara Isakova; Karen Laliberte; Kelsey Smith; Gina Collerone; Ammar Sarwar; Udo Hoffmann; Erin Coglianese; Robert Christenson; Thomas J Wang; Christopher deFilippi; Myles Wolf
Journal:  Circulation       Date:  2009-05-04       Impact factor: 29.690

9.  Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population.

Authors:  Majd A I Mirza; Anders Larsson; Håkan Melhus; Lars Lind; Tobias E Larsson
Journal:  Atherosclerosis       Date:  2009-05-21       Impact factor: 5.162

10.  Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.

Authors:  Chaofeng Yang; Chengliu Jin; Xiaokun Li; Fen Wang; Wallace L McKeehan; Yongde Luo
Journal:  PLoS One       Date:  2012-03-19       Impact factor: 3.240
View more
  126 in total

1.  FGF23 contains two distinct high-affinity binding sites enabling bivalent interactions with α-Klotho.

Authors:  Yoshihisa Suzuki; Ekaterina Kuzina; Seong J An; Francisco Tome; Jyotidarsini Mohanty; Wenxue Li; Sangwon Lee; Yansheng Liu; Irit Lax; Joseph Schlessinger
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-30       Impact factor: 11.205

2.  Characterization of fibroblast growth factor 1 in obese children and adolescents.

Authors:  Anru Wang; Xueqin Yan; Cai Zhang; Caiqi Du; Wenjun Long; Di Zhan; Xiaoping Luo
Journal:  Endocr Connect       Date:  2018-07-10       Impact factor: 3.335

3.  Ursodeoxycholic acid exerts hepatoprotective effects by regulating amino acid, flavonoid, and fatty acid metabolic pathways.

Authors:  Da Jung Kim; Hyewon Chung; Sang Chun Ji; SeungHwan Lee; Kyung-Sang Yu; In-Jin Jang; Joo-Youn Cho
Journal:  Metabolomics       Date:  2019-02-27       Impact factor: 4.290

Review 4.  Fibroblast growth factors 19 and 21 in acute liver damage.

Authors:  Zhao Shan; Gloria Alvarez-Sola; Iker Uriarte; María Arechederra; Maite G Fernández-Barrena; Carmen Berasain; Cynthia Ju; Matías A Avila
Journal:  Ann Transl Med       Date:  2018-06

Review 5.  The ever-expanding myokinome: discovery challenges and therapeutic implications.

Authors:  Martin Whitham; Mark A Febbraio
Journal:  Nat Rev Drug Discov       Date:  2016-09-12       Impact factor: 84.694

6.  TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.

Authors:  Lipika Goyal; Lei Shi; Leah Y Liu; Ferran Fece de la Cruz; Jochen K Lennerz; Srivatsan Raghavan; Ignaty Leschiner; Liudmila Elagina; Giulia Siravegna; Raymond W S Ng; Phuong Vu; Krushna C Patra; Supriya K Saha; Raul N Uppot; Ron Arellano; Stephanie Reyes; Takeshi Sagara; Sachie Otsuki; Brandon Nadres; Heather A Shahzade; Ipsita Dey-Guha; Isobel J Fetter; Islam Baiev; Emily E Van Seventer; Janet E Murphy; Cristina R Ferrone; Kenneth K Tanabe; Vikram Deshpande; James J Harding; Rona Yaeger; Robin K Kelley; Alberto Bardelli; A John Iafrate; William C Hahn; Cyril H Benes; David T Ting; Hiroshi Hirai; Gad Getz; Dejan Juric; Andrew X Zhu; Ryan B Corcoran; Nabeel Bardeesy
Journal:  Cancer Discov       Date:  2019-05-20       Impact factor: 39.397

7.  2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors.

Authors:  Cheng Mo; Zhang Zhang; Christopher P Guise; Xueqiang Li; Jinfeng Luo; Zhengchao Tu; Yong Xu; Adam V Patterson; Jeff B Smaill; Xiaomei Ren; Xiaoyun Lu; Ke Ding
Journal:  ACS Med Chem Lett       Date:  2017-03-31       Impact factor: 4.345

Review 8.  Pathology of Human Coronary and Carotid Artery Atherosclerosis and Vascular Calcification in Diabetes Mellitus.

Authors:  Kazuyuki Yahagi; Frank D Kolodgie; Christoph Lutter; Hiroyoshi Mori; Maria E Romero; Aloke V Finn; Renu Virmani
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-12-01       Impact factor: 8.311

9.  Rotational Freedom, Steric Hindrance, and Protein Dynamics Explain BLU554 Selectivity for the Hinge Cysteine of FGFR4.

Authors:  Xiaojing Lin; Yuliana Yosaatmadja; Maria Kalyukina; Martin J Middleditch; Zhen Zhang; Xiaoyun Lu; Ke Ding; Adam V Patterson; Jeff B Smaill; Christopher J Squire
Journal:  ACS Med Chem Lett       Date:  2019-07-03       Impact factor: 4.345

Review 10.  The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic.

Authors:  Leiluo Geng; Karen S L Lam; Aimin Xu
Journal:  Nat Rev Endocrinol       Date:  2020-08-06       Impact factor: 43.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.